Nevro receives two key U.S. patents for Senza High-Frequency Spinal Cord Stimulation System

Nevro Corp., a medical device company focused on improving pain relief among patients suffering from debilitating chronic pain, announced today the issuance of two key patents related to the company's Senza™ High-Frequency Spinal Cord Stimulation System.

U.S. Patent No. 8,170,675 includes multiple claims directed to methods for delivering pulsed electrical signals to the epidural space of the spinal cord at frequencies between about 1.5 kHz and about 50 kHz to relieve a patient's chronic leg and/or back pain without creating paresthesia. Paresthesia is typically a tingling, buzzing sensation associated with conventional low-frequency spinal cord stimulation systems that patients often find unpleasant.

An additional patent, No. 8,209,021, includes medical apparatus claims that correspond to many of the method claims of U.S. Patent No. 8,170,675.

"We believe these patents validate the distinct nature of our technology," said Nevro's President and Chief Executive Officer Michael DeMane. "Their issuance represents an important milestone in the development of the technology and underscores Nevro's position at the forefront of innovation in the field of spinal cord stimulation."

Further patent applications covering many other aspects of Nevro's proprietary technology are pending in the U.S. and abroad.